Association between Pruritus and Serum Concentrations of Parathormone, Calcium and Phosphorus in Hemodialysis Patients

Similar documents
Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Sensipar. Sensipar (cinacalcet) Description

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

Therapeutic golas in the treatment of CKD-MBD

Diagnosis and Treatment of Sagliker Syndrome A Case Series From Iran

Downloaded from umj.umsu.ac.ir at 7: on Wednesday October 3rd 2018

INTERNATIONAL JOURNAL OF RESEARCH SCIENCE & MANAGEMENT

Should cinacalcet be used in patients who are not on dialysis?

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):

The Efficacy and Safety of 6% Gabapentin Topical Formulation in The Treatment of Pruritus in Adult Filipino Hemodialysis Patients:

Secondary Hyperparathyroidism: Where are we now?

Itchy skin a clinical problem for haemodialysis patients

Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer

MANAGEMENT OF CALCIUM AND PHOSPHORUS METABOLISM IN CHRONIC KIDNEY DISEASE PATIENTS

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Sensipar (cinacalcet)

CR845 s Potential for Chronic Kidney Disease-Associated Pruritus

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

- =>? - 1 D /" + B*

Month/Year of Review: September 2012 Date of Last Review: September 2010

International Journal of Health Sciences and Research ISSN:

Skin and serum levels of calcium, phosphorus and vitamin D3 in uremic pruritus patients before and after broad band ultraviolet B (UVB) phototherapy

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

The Parsabiv Beginner s Book

Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism

Third Day. Thursday, November 24

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

Improvement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis

Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran

The Effect of High-Flux Hemodialysis on Dialysis-Associated Amyloidosis

Corporate Presentation January 2013

Relationship of bone density with serum parathyroid hormone in hemodialysis patients; a single center study

Report and Opinion 2016;8(12)

Uremic pruritus. SR Keithi-Reddy 1, TV Patel 2, AW Armstrong 3 and AK Singh 2. the renal consult

Pulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis

Secondary hyperparathyroidism an Update on Pathophysiology and Treatment

Calcium ions are abnormally distributed in the skin of haemodialysis patients with uraemic pruritus

Vitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients

Research Article Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi

Advances in Peritoneal Dialysis, Vol. 29, 2013

Technetium-99m Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism

Links to the following videos are also available online underneath the article abstract.

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

A Descriptive Cross Sectional Study to Determine Mucocutaneous Manifestations in Chronic Renal Failure on Hemodialysis

Modern Medical Laboratory Journal - ISSN X

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.

OPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura

NATIONAL QUALITY FORUM Renal EM Submitted Measures

Bone Disorders in CKD

ORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

Profile of mineral bone disease in Pre-dialytic stage 3-5 Chronic Kidney Disease Patients: A Cross-Sectional Study

Association of Parathyroid Hormone with Markers of Bone-Mineral Metabolism in Patients of Chronic Kidney Disease with Secondary Hyperparathyroidism

White Rose Research Online URL for this paper: Version: Accepted Version

ORIGINALARTICLE. Introduction JK SCIENCE

Changing Epidemiology of End-Stage Renal Disease in Last 10 Years in Iran

THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION

Parathyroid hormone or fibroblast growth factor 23? Which one is the main determinant of the hypophosphatemia after kidney transplantation?

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES

Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy

Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1

The Effectiveness and Cost-Effectiveness of Cinacalcet for the Treatment of Hyperparathyroidism Secondary to Impaired Renal Function

PART FOUR. Metabolism and Nutrition

Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS

PREDICTIVE FACTORS FOR PERSISTENT HYPERPARATHYROIDISM AFTER KIDNEY TRANSPLANTATION

Calcium x phosphate product

Parathyroid hormone levels in long-term renal transplant children and adolescents

Ying Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1.

Metabolic Bone Disease (Past, Present and Future Challenges in the Management)

Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:

This review examines the dynamics of parathyroid hormone

... . : ... PTH.

Efficacy of intraoperative parathyroid hormone monitoring to predict success of parathyroidectomy for secondary hyperparathyroidism

Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients at Al-Shifa Hospital, Gaza-Palestine

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis

Disturbed skin barrier in children with chronic kidney disease

Uremic Pruritis: Hit me so I can feel something other than itch

C ardiovascular disease (CVD) and stroke are the main causes of morbidity and

The relationship between parathyroid enlargement and parathyroid hormone levels in patients undergoing hemodialysis; EMR(Electronic Medical Record)

2.0 Synopsis. ABT-358/Paricalcitol M Clinical Study Report R&D/09/1255. (For National Authority Use Only) to Part of Dossier: Volume:

Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism

Montelukast for Treatment of Refractory Pruritus in Patients on Hemodialysis

Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients

Self-care Behavior and Physical Factors in Elderly Hemodialysis Patients

CCRN Review - Renal. CCRN Review - Renal 10/16/2014. CCRN Review Renal. Sodium Critical Value < 120 meq/l > 160 meq/l

Nephrology. dialysis. Transplantation. Pruritus and skin hydration during dialysis. Original Article

Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?

PART FOUR. Metabolism and Nutrition

Transcription:

Saudi J Kidney Dis Transpl 2013;24(4):702-706 2013 Saudi Center for Organ Transplantation Original Article Saudi Journal of Kidney Diseases and Transplantation Association between Pruritus and Serum Concentrations of Parathormone, Calcium and Phosphorus in Hemodialysis Patients Ramin Tajbakhsh 1, Hamid Reza Joshaghani 2, Faranak Bayzayi 3, Mahboobeh Haddad 4, Mostafa Qorbani 5 1 Department of Nephrology, 2 Liver and Gastroentrology Research Center, 3 Kalaleh Therapeutic Center, 4 Golestan University of Medical Sciences, Golestan; 5 Epidemiology Department, Tehran University of Medical Sciences, Tehran, Iran ABSTRACT. Chronic renal disorders have a progressive course in most cases, and finally result in end-stage renal disease (ESRD). Hemodialysis (HD) is one of the mainstays in the treatment of these patients. Disturbance in calcium (Ca) and phosphorus (P) metabolism and alteration of serum levels of parathormone (PTH) are observed in these patients. One of the most common cutaneous manifestations in patients on HD is pruritus. The aim of this study is to evaluate the association between pruritus and serum concentrations of Ca, P and PTH in patients with chronic renal disease. This analytic, descriptive, cross-sectional study was performed on 120 patients on HD at the Fifth-Azar Hospital in Gorgan, Iran, in 2010. Information related to the patients, including age, gender, pruritus, time of pruritus and duration on dialysis, was extracted from questionnaires. Serum concentrations of intact PTH, Ca and P were measured. Data were analyzed by the chi-square test and SPSS-16 software. A P-value less than 0.05 was considered statistically significant. Among the 120 study patients, 50% were male and the mean age (±SD) was 49 ± 12.3 years. Sixty percent of the patients had pruritus, of whom 33.3% had PTH levels above the normal range. Among the 40% of the patients who did not have pruritus, 39.6% had PTH levels higher than the normal levels. The mean serum Ca and P levels were 8.44 ± 1.65 mg/dl and 5.48 ± 1.81 mg/dl, respectively. The mean (±SD) Ca P product was 55.46 ± 47.16 and the mean PTH concentration was 274.34 ± 286.53 pg/ml. No significant association was found between pruritus and age, sex, serum PTH and P levels as well as Ca P product. However, the association between serum Ca levels and pruritus was significant (P = 0.03). Our study showed that most patients with pruritus had serum Ca levels in the abnormal range (lower or higher), and there was no significant correlation between serum ipth level and pruritis. Thus, good control of serum Ca levels is important to reduce pruritus in these patients. Correspondence to: Dr. Ramin Tajbakhsh, Department of Nephrology, Golestan University of Medical Sciences, Golestan, Iran E-mail: r_tajbakhsh@yahoo.com Introduction Chronic renal disease has a progressive course in most cases, and finally results in end-stage renal disease (ESRD). Various treatments have been considered for these patients,

Pruritus and parathormone, calcium, and phosphorus in HD patients 703 and one of the main options is hemodialysis (HD). 1 Patients with renal failure who are on treatment with HD suffer from mucosal and cutaneous lesions, which often annoy patients. These mucocutaneous manifestations may be related to uremia, previous underlying disease, drugs and/or HD treatment. 2 The serum levels of calcium (Ca), phosphorus (P) and parathormone (PTH) are the most important biochemical factors that get altered in these patients. One of the most common complications seen in patients on HD is pruritus, the prevalence of which in patients with chronic renal failure (CRF) is between 37% and 90%; this rate is about 80% in patients on HD. 3 The etiology of pruritus has not been completely understood in these patients and its pathophysiology depends on several factors. In chronic kidney disease (CKD), there is elevated PTH concentration secondary to derangement of Ca, P and vitamin D metabolism. Generally, hyperphosphatemia, hypocalcemia and decreased calcitriol production can all increase the PTH production and hyperplasia of parathyroid cells, finally resulting in secondary hyperparathyroidism. 4 Hyperparathyroidism can stimulate mast cells to release histamine and increase deposition of Ca and magnesium salts on the skin. However, not all patients with severe hyperparathyroidism have pruritus. In addition, in some of the studies, no association has been found between plasma levels of PTH and cutaneous proliferation and number of mast cells. 5 In view of the high prevalence of pruritus in patients on dialysis and its unknown etiology as well as the lack of a safe treatment for pruritus, further investigations in this field are necessary. The aim of this study is to evaluate the association between pruritus and serum levels of PTH, Ca and P in patients on HD. Materials and Methods This descriptive analytic, cross-sectional study was conducted on 120 patients who were on HD at the Fifth-Azar Hospital in Gorgan in 2010. The diagnosis of ESRD was confirmed by the nephrologists. Data were collected from questionnaires, and included age, gender, pruritus, time of developing pruritus and duration on HD. ipth was measured by the enzymelinked immunosorbent assay, Ca by CPC and a spectrophotometer and P by the ultraviolet technique. According to the Kidney Diseases Outcome and Quality Initiative, the acceptable level of serum Ca in patients with ESRD is 8.4 9.5 mg/dl, of P is 3.5 5.5 mg/dl and of ipth is 150 300 pg/ml. Age, as a qualitative variable, was considered in three groups (15 35, 35 55 and 55 75 years). Data were analyzed by the chi-square test and SPSS-16 software. A P-value less than 0.05 was considered as being statistically significant. Results Among the 120 HD patients studied, half were males. The mean age ± standard deviation was 49 ± 12.3 years, duration on dialysis was 3.84 ± 4.05 years, serum Ca concentration was 8.44 ± 1.65 m/dl, serum PTH level was 274.34 ± 286.53 pg/ml, serum P level was 5.48 ± 1.81 mg/dl and Ca P product was 55.46 ± 47.16. In this study, 60% of the patients had pruritus; the PTH was higher than normal in 33.3% of them. In contrast, 39.6% of the patients without pruritus had high PTH concentrations. The association of pruritus and independent variables has been shown in Table 1. As shown, pruritus had no statistically significant difference between the two genders (P = 1.00). The serum PTH concentration was below normal in 55%, normal in 9.16% and above the normal limit in 35.83% of the patients. No significant association was found between age, gender, serum PTH, serum P levels and the Ca P product and pruritus, while the association between serum Ca level and pruritus was significant (P = 0.03). The serum Ca was below normal in 54.2% of the patients with pruritus and 44.7% of patients without pruritus. The prevalence of pruritus, before or after dialysis, had no relationship with serum Ca and P levels (P > 0.05). The serum Ca and P levels showed no significant association with the serum PTH level (P >0.05). The association

704 Tajbakhsh R, Joshaghani HR, Bayzayi F, Haddad M, Qorbani M Table 1. Association between pruritus and independent variables in the study subjects. Variables Classification With pruritus Without pruritus No. (%) No. (%) Gender Male 36 (50) 24 (50) Female 36 (50) 24 (50) 15 35 years 10 (13.9) 13 (27.1) Age groups 35 55 years 37 (51.4) 19 (39.6) 55 75 years 25 (34.7) 16 (33.3) Higher than normal 29 (40.3) 22 (45.8) Serum phosphorus level Normal 37 (51.4) 21 (43.8) Lower than normal 6 (8.3) 5 (10.4) Higher than normal 19 (26.4) 7 (14.9) Serum calcium level Normal 14 (19.4) 19 (40.4) Lower than normal 39 (54.2) 21 (44.7) Calcium phosphorus product More than 55 18 (25) 13 (27.1) Less than 55 54 (75) 35 (72.9) Higher than normal 24 (33.3) 19 (39.6) Serum parathormone level Normal 6 (8.3) 5 (10) Lower than normal 42 (58.3) 24 (50) P- value 0.03 between Ca P product and serum PTH in the study patients according to gender and age groups is summarized in Table 2. The only significant association seen was in the serum PTH levels in the various age groups (P <0.01); the age group 15 35 years had higher serum PTH levels while most of the other age groups had lower PTH levels. Discussion In this study, pruritus was found in 60% of the patients. In previous studies, the reported prevalence of pruritus has been higher, while in some other studies, it has been lower than that in our study. For instance, pruritus was observed in 58.8% of the patients by Szepietowski, 6 41.9% by Akhiani et al, 7 70% by Yazdanpanah et al 8 and 72.8% by Omori Kentaro et al from Japan. 9 These differences may be due to the prevailing climatic conditions. Comparison of these results shows that, generally, more than half of the patients complained of pruritus in most studies. In the study by Narita et al, there was a significant association between serum PTH levels and pruritus. 10 In the study by Yazdanpanah, the serum PTH level was normal in 60% of the patients and 84% complained of pruritus. They found a significant difference in the serum PTH levels in patients with and without pruritus. 8 In addition, Stable-backdahlm et al also reported that the serum PTH level in HD patients with pruritis was significantly higher than in those without pruritus. However, no association was found between the severity of Table 2. The association of calcium phosphorus product and serum parathormone with gender and age groups in the study subjects. Calcium phosphorus Serum parathormone level product Variable Less than More Less than More than Normal 55 than 55 P normal normal P No. (%) No. (%) No. (%) No. (%) No. (%) Male 47 (54) 12 (38.7) 30 (45.5) 7 (63.6) 23 (53.5) Gender Female 40 (46) 19 (61.3) 36 (54.5) 4 (36.4) 20 (46.5) Age groups (years) 15 35 15 (17.2) 8 (25.8) 5 (7.6) 3 (27.3) 15 (34.9) 35 55 39 (44.8) 15 (48.4) 32 (48.5) 7 (63.6) 17 (39.5) 55 75 33 (37.9) 8 (25.8) 29 (43.9) 1 (9.1) 11 (25.6) <0.01

Pruritus and parathormone, calcium, and phosphorus in HD patients 705 symptoms and the serum PTH levels. 11 In the present study, contrary to the three previous studies, the serum PTH concentration in patients with and without pruritus showed no significant difference (P = 0.66). This finding is similar to the results of Kakuu et al, 12 Akhiyani et al 7 and Szepietowski et al, 6 in which no significant association was found between pruritus and serum PTH levels. Narita et al and Omori Kentaro et al, in their studies, showed that male gender was an important factor for developing severe pruritus; 9,10 in our study, there was no statistically significant association between pruritus and male and female genders (P = 1.00). Omori Kentaro et al reported a significant association between pruritus and age; age younger than 30 years was associated with a lower risk for pruritus, 10 and no significant association was found between age and pruritus in our study. Narita et al and Szepietowski et al found that the serum Ca concentration was significantly higher in patients with pruritus when compared with those without pruritus. 6,10 In the present study, majority of the cases with pruritus had abnormal (increased or decreased) serum Ca levels (Table 1). A reverse association was seen between pruritus and serum Ca level in our study. Some other investigators however found no significant association between serum Ca and pruritus. 7,11 Additionally, many studies found no association between serum P levels and pruritus. 7,8,13 These findings were similar to our study, although Omori Kentaro et al reported a significant association between hyperphosphatemia and pruritus. 10 Many studies have reported a significant association between the Ca P product and pruritus. 9,14 The strong points in our study are including ipth measurement and excluding patients with cutaneous lesions; whereas, the small sample size is a limitation in our study. In conclusion, our study revealed a significant association between serum Ca levels and cutaneous pruritus. No significant correlation was found between serum ipth level and pruritis. Thus, in patients with ESRD, it is important to maintain the serum Ca levels at as close to normal as possible to reduce the prevalence of pruritus. References 1. Arend, Armitage, Clemmons, Cecil Medicin, 23 rd ed, Vol. 1, Chapter 131, Chronic Kidney Disease, 2008. 2. Banerjee S. Cutaneous manifestations in renal failure patients: Acase series. Indian J Dermatol Venereol Leprol 2007;73:106-8. 3. Ghaderi R, Mohamadi-Fard M. Comparison of effectiveness of emollients and heliotherapy for pruritus relief in hemodialysis patients. Horizon of Medical Sciences 2006;12(1):42-7. 4. Harrisson. Internal Medicine Principals. Renal and urinary tract disorderes. Translated by Shafiee A, Mahdavi-Mazdeh M. Chapter 261, 2005. p. 90-106. 5. Ostlere LS, Taylor C, Baillod R, Wright S. Relationship between pruritus, transepidermal water loss, and biochemical markers of renal itch in haemodialysis patients. Nephrol Dial Transplant 1994;9:1302-4. 6. Szepietowski J. Selected elements of the pathogenesis of pruritus in hemodialysis patients: My own study. Med Sci Monit 1996; :343-7. 7. Akhyani M, Ganji M, Samadi N, Khamesan B, Daneshpazhooh M. Pruritus in hemodialysis patients. BMC Dermatol 2005;5:7. 8. Yazdanpanah M, Mojahedi M, Ebrahimi Rad M, Birjandi M. Cutaneous manifestations in hemodialysis patients with chronic renal failure. Mashhad Univ Med Sci J 2006;25:92, 509. 9. Kentaro O, Ikuo I, Haruki A, et al. Risk factors for uremic pruritus in long-term hemodialysis patients. J Jpn Soc Dial Ther 2001;12;1469-77. 10. Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006;69:1626-32. 11. Kuypers D, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uremic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004;19,1895-901. 12. Kaku H, Fujita Y, Yago H, et al. study on pruritus in hemodialysis patients and the anti pruritic effect of neurotropin: Plasma levels of substance P, somatostatin, IgE, PTH and

706 Tajbakhsh R, Joshaghani HR, Bayzayi F, Haddad M, Qorbani M histamine. Nippon Jinzo Gakkai Shi 1990;32: 319-26. 13. Mirnezami M, Rahimi H. Factors associated with uremic pruritus in patients undergoing hemodialysis: A report from Arak Valiasr Hospital. Iran J Dermatol 2010;13:12-5. 14. Chou FF, Ho JC, Huang SC, Sheen-Chen SM. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 2000;190:65-70.